Pharma Marketing Network

Yesterday, I posted a commentary about the imagery of the new DTC ads for Rozerem, a sleep aid drug from Takeda Pharmaceuticals (see "Rozerem...

I'm trying to figure out the thinking behind the new DTC (direct to consumer) ad campaign for Rozerem, the new sleep aid pill...

On her lunch break, while innocently reading the latest issue of Woman's Day magazine, Emily Jameson, mild-mannered summer intern at PhRMA -- America's pharmaceutical...

The Premier Conference Convening Manufacturers and Part D Plans to Assess Implementation, Develop Sustainable Strategies and Ensure Compliance

The Premier Conference Convening Manufacturers and Part D Plans to Assess Implementation, Develop Sustainable Strategies and Ensure Compliance

As reported in yesterday's Wall Street Journal, "Awaiting approval from U.S. regulators to sell an over-the-counter diet pill called Alli, GlaxoSmithKline PLC has set...

Last week I reported on PhRMA's tardy response to my complaint about Sepracor's violation of PhRMA's DTC Guiding Principles (see "PhRMA's Response - PRwise,...

An article entitled "The Marketing Maze" in a special marketing section of yesterday's Wall Street Journal presents a breakdown of US advertising expenditures for...

There are several key areas that will be discussed and debated during this program, including Safety Data Analysis, a risk management framework for drug safety research, the FDA’s guidance document on Post-Marketing Risk Assessment, Good Pharmacovigilancve Practices & Pharmacoepidemiologic Assessment, strategies for effective data transparency and corporate image management, emerging technologies to streamline risk management in drug safety reporting and post-marketing surveillance and best practices in the analysis of this data as well as optimal methods of information delivery.

My post yesterday regarding PhRMA's response to my letter citing a violation of its DTC Guiding Principles by Sepracor (see "PhRMA's Response - PRwise,...